Business
Resverlogix Completes Dosing In ASSURE Clinical Trial
IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Diseas...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n\n\nIVUS data will evaluate plaque regression in patients with high-risk\n Cardiovascular Disease \n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, April 18, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) today\n announced that it has completed dosing in ASSURE, a Phase 2b clinical\n trial evaluating RVX-208, Resverlogix's first-in-class orally active\n BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in\n high-risk cardiovascular patients with low HDL and ApoA-I (n=324).\n These target patients have significant residual risk in major adverse\n coronary events (MACE) such as heart attack, unstable angina, stroke,\n revascularization and death, despite standard of care therapy such as\n statins. The main underlying cause of the residual risk in these\n patients is atherosclerosis. ASSURE is designed to evaluate the ability\n of RVX-208 to regress atherosclerotic disease.\n\n\n\"Atherosclerosis regression represents a new paradigm in the treatment\n of high-risk cardiovascular disease patients,\" said Donald McCaffrey,\n president and chief executive officer of Resverlogix. \"The completion\n of the ASSURE trial is a major development milestone for the company.\n RVX-208 is the first small molecule BET inhibitor that raises the\n production of ApoA-I to be tested in a landmark IVUS trial.\"\n\n\nASSURE is a 26-week, multi-center, double-blind, randomized, parallel\n group, placebo-controlled trial led by the Cleveland Clinic. To assess\n atherosclerosis regression in ASSURE, all subjects were examined using\n IVUS. The primary endpoint in ASSURE is to detect a change in percent\n atheroma volume as determined by IVUS at baseline vs. 26 weeks of\n treatment. The use of IVUS technology will provide details regarding\n plaque composition and stability, which is important because both are\n elements leading to acute coronary syndrome. Secondary endpoints for\n ASSURE include safety and tolerability of RVX-208, effects of the\n compound on plasma ApoA-I, HDL-C, HDL-subclasses and non-HDL lipid\n parameters such as the CRP inflammation marker. Top line data is\n expected mid-2013.\n\n\nAbout RVX-208\n\n\nRVX-208 is a first-in-class small molecule that inhibits BET\n bromodomains. RVX-208 functions by removing atherosclerotic plaque via\n reverse cholesterol transport (RCT), the natural process through which\n atherosclerotic p...